N-terminal-proB-type natriuretic peptide predicts cardiovascular disease events in HIV-infected patients

Daniel Duprez; Jacqueline Neuhaus; Russell Tracy; Lewis Kuller; Steven Deeks; Chloe Orkin; Albrecht Stoehr; Ian Woolley; James Neaton

doi:10.1097/QAD.0b013e32834404a1

N-terminal-proB-type natriuretic peptide predicts cardiovascular disease events in HIV-infected patients

Daniel Duprez, Jacqueline Neuhaus, Russell Tracy, Lewis Kuller, Steven Deeks, Chloe Orkin, Albrecht Stoehr, Ian Woolley, James Neaton

Medicine Monash Health

Research output: Contribution to journal › Article › Research › peer-review

27 Citations (Scopus)

Abstract

Cardiovascular disease (CVD) is increasing in HIV-infected patients. N-terminal pro-B-type natriuretic peptide (NT-proBNP) is a significant predictor of CVD in the general population. We aimed to quantify the risk of CVD events associated with NT-proBNP at baseline in the Strategies for Management of Anti-Retroviral Therapy study. METHODS: In a nested case-control study, NT-proBNP was measured at baseline in 186 patients who experienced a CVD event over an average of 2.8 years of follow-up and in 329 matched controls. Odds ratios (ORs) associated with baseline levels of NT-proBNP for CVD were estimated using conditional logistic regression.

Original language	English
Pages (from-to)	651 - 657
Number of pages	7
Journal	AIDS
Volume	25
Issue number	5
DOIs	https://doi.org/10.1097/QAD.0b013e32834404a1
Publication status	Published - 2011

Access to Document

10.1097/QAD.0b013e32834404a1

RM sElocation

Cite this

@article{134dc70caa7f40e88af3a93ceed3e809,

title = "N-terminal-proB-type natriuretic peptide predicts cardiovascular disease events in HIV-infected patients",

abstract = "Cardiovascular disease (CVD) is increasing in HIV-infected patients. N-terminal pro-B-type natriuretic peptide (NT-proBNP) is a significant predictor of CVD in the general population. We aimed to quantify the risk of CVD events associated with NT-proBNP at baseline in the Strategies for Management of Anti-Retroviral Therapy study. METHODS: In a nested case-control study, NT-proBNP was measured at baseline in 186 patients who experienced a CVD event over an average of 2.8 years of follow-up and in 329 matched controls. Odds ratios (ORs) associated with baseline levels of NT-proBNP for CVD were estimated using conditional logistic regression.",

author = "Daniel Duprez and Jacqueline Neuhaus and Russell Tracy and Lewis Kuller and Steven Deeks and Chloe Orkin and Albrecht Stoehr and Ian Woolley and James Neaton",

year = "2011",

doi = "10.1097/QAD.0b013e32834404a1",

language = "English",

volume = "25",

pages = "651 -- 657",

journal = "AIDS",

issn = "0269-9370",

publisher = "Lippincott Williams & Wilkins",

number = "5",

}

N-terminal-proB-type natriuretic peptide predicts cardiovascular disease events in HIV-infected patients. / Duprez, Daniel; Neuhaus, Jacqueline; Tracy, Russell; Kuller, Lewis; Deeks, Steven; Orkin, Chloe; Stoehr, Albrecht; Woolley, Ian; Neaton, James.

In: AIDS, Vol. 25, No. 5, 2011, p. 651 - 657.

Research output: Contribution to journal › Article › Research › peer-review

TY - JOUR

T1 - N-terminal-proB-type natriuretic peptide predicts cardiovascular disease events in HIV-infected patients

AU - Duprez, Daniel

AU - Neuhaus, Jacqueline

AU - Tracy, Russell

AU - Kuller, Lewis

AU - Deeks, Steven

AU - Orkin, Chloe

AU - Stoehr, Albrecht

AU - Woolley, Ian

AU - Neaton, James

PY - 2011

Y1 - 2011

N2 - Cardiovascular disease (CVD) is increasing in HIV-infected patients. N-terminal pro-B-type natriuretic peptide (NT-proBNP) is a significant predictor of CVD in the general population. We aimed to quantify the risk of CVD events associated with NT-proBNP at baseline in the Strategies for Management of Anti-Retroviral Therapy study. METHODS: In a nested case-control study, NT-proBNP was measured at baseline in 186 patients who experienced a CVD event over an average of 2.8 years of follow-up and in 329 matched controls. Odds ratios (ORs) associated with baseline levels of NT-proBNP for CVD were estimated using conditional logistic regression.

AB - Cardiovascular disease (CVD) is increasing in HIV-infected patients. N-terminal pro-B-type natriuretic peptide (NT-proBNP) is a significant predictor of CVD in the general population. We aimed to quantify the risk of CVD events associated with NT-proBNP at baseline in the Strategies for Management of Anti-Retroviral Therapy study. METHODS: In a nested case-control study, NT-proBNP was measured at baseline in 186 patients who experienced a CVD event over an average of 2.8 years of follow-up and in 329 matched controls. Odds ratios (ORs) associated with baseline levels of NT-proBNP for CVD were estimated using conditional logistic regression.

UR - http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3113476/pdf/nihms294978.pdf

U2 - 10.1097/QAD.0b013e32834404a1

DO - 10.1097/QAD.0b013e32834404a1

M3 - Article

VL - 25

SP - 651

EP - 657

JO - AIDS

JF - AIDS

SN - 0269-9370

IS - 5

ER -